"SUPER CITRIMAX(R) CLINICAL STRENGTH"
                               LICENSING AGREEMENT

This Licensing Agreement ("Agreement") is entered into as of June 7, 2004
("Effective Date"), between InterHealth Nutraceuticals Incorporated, a
California corporation ("Company"), and the licensee identified on the signature
page of this Agreement ("Licensee").

WHEREAS, Company markets, distributes and sells a standardized calcium/potassium
(-)hydroxycitric acid product described in Exhibit A attached hereto
("Product"), which:

     (a)  is sold as nutritional supplement,

     (b)  is the subject of various U.S. and PCT patents pending described in
          Exhibit A attached hereto, as well as other patents pending, which may
          be applied for in the future ("Patents Pending"),

     (c)  is the subject of various research studies described in Exhibit B
          attached hereto, as well as other research studies, which may be
          conducted and published in the future ("Research"),

     (d)  is the subject of various product claims covered by the Patents
          Pending and supported by the Research ("Product Claims"), and

     (e)  is sold under the tradename "Super CitriMax Clinical Strength"
          ("Trademark")

("Licensed Product").

WHEREAS, A) Company is the owner of all right, title and interest in the (i)
Patents Pending, including any continuation-in-parts, divisional and reissue
applications, and any patents resulting therefrom ("Patent Rights"), and (ii)
Trademark, including variations thereof and any registrations which may exist
therefore, for its Licensed Product, B) Licensee desires to sell, market and
distribute finished product(s) that contain Licensed Product to be packaged by
Licensee in end-user, finished packaged form as a nutritional supplement (each a
"Finished Product," collectively "Finished Products"), and to use the Trademark,
Product Claims and Research in connection with sales of its Finished Products;
and C) Company is willing to (i) sell Product to Licensee, or Licensee's
designated contract manufacturer(s), and (ii) grant Licensee the right to use
the Trademark, Product Claims and Research in connection with the sale of
Licensee's Finished Products.

NOW, THEREFORE, the parties agree as follows:

     1.   TRADEMARK OWNERSHIP - Licensee agrees that:

          (a)  Company is the sole and exclusive owner of all right, title and
               interest in, and to, the Trademark and Patent rights;

          (b)  Licensee shall not challenge or question the validity of, or
               Company's title to, the Trademark or Patent Rights; and

          (c)  with the exception of the rights being licensed under this
               Agreement, all other rights relating to the Trademark and Patent
               Rights are the property of the Company and Licensee shall not
               acquire any other rights to the Trademark or Patent Rights.

     2.   BUY/SELL AGREEMENT - Company agrees to sell Product to Licensee or
          Licensee's designated contract manufacturer(s) of Finished Products
          (each a "Contract Manufacturer," collectively "Contract
          Manufacturers"), and Licensee or Licensee's Contract Manufacturers,
          whichever the case may be, agree to purchase Product exclusively from
          Company at prices, terms and conditions acceptable to Company and
          Licensee and/or Licensee's Contract Manufacturers, whichever the case
          may be, and other terms and conditions specified in this Agreement.

     3.   GRANT OF LICENSE - Company grants to Licensee, and Licensee accepts, a
          non-exclusive, non-transferable, royalty-free license to use the
          Trademark, Product Claims and Research solely in connection with the
          marketing and distribution of Finished Products that contain Product
          in the manner, and on the terms and conditions, specified in this
          Agreement. InterHealth represents that to the best of its knowledge,
          information, and belief (a) the Research has been conducted in
          accordance with good scientific standards and practices, and (b) the
          Product Claims are substantiated by the Research.

     4.   USE OF TRADEMARK - Licensee shall:

          (a)  use the Trademark, Product Claims and Research solely in
               connection with:

               (i)  the Licensed Product purchased from Company, and

               (ii) Finished Product that is in compliance with this Agreement;

          (b)  display the Trademark on, or in, all labeling, advertising and
               promotional



               materials of its Finished Products in a manner that clearly
               associates the Trademark with the licensed Product;

          (c)  display or reproduce the Trademark only in:

               (i)  the appropriate logo style specified in Exhibit C attached
                    to this Agreement (electronic file of the Trademark logo to
                    be provided to Licensee by Company upon execution of this
                    Agreement); or

               (ii) type-written form only if used in secondary labeling,
                    advertising and promotional copy (i.e. in a sentence or
                    paragraph describing the Licensed Product), and so long as
                    the Super CitriMax trademark is accompanied by the "(R)"
                    symbol and identified as a trademark of InterHealth N.I.;
                    and

          (d)  not use, display or relate in any manner, either directly or
               indirectly, the Trademark, Product Claims or Research in
               connection with any products that do not contain Licensed Product
               and are not subject to this Agreement.

     5.   PRODUCT INFORMATION AND MATERIALS - Company provides, and will
          provide, Licensee information and materials relating to Licensed
          Product, whether proprietary or non-proprietary, whether written,
          recorded or verbal, whether on, prior or subsequent to the date of
          this Agreement, whether prepared by Company or by a third party,
          including, but not limited to, all Licensed Product sales and
          marketing materials, research data and other technical information in
          good faith and which InterHealth believes to be true and accurate
          ("Information" and "Materials"), "As Is, With All Faults," and makes,
          and will make, no representations or warranties, express or implied,
          as to the usefulness, accuracy, completeness, feasibility, reliability
          or legality of the Information and Materials. Licensee may use all
          Information and Materials prepared by or for Company solely in
          connection with the marketing and distribution of Licensed Product
          purchased from the Company or Finished Products that contain Licensed
          Product purchased from the Company and not in connection with any
          products that do not contain Licensed Product and are not subject to
          this Agreement; provided that Licensee does not in any way alter any
          of the Materials. Company may amend, add to, subtract from or
          otherwise change from time to time, the Information and/or Materials,
          in its sole and absolute discretion.

     6.   UNDERTAKINGS BY LICENSEE:

          (A)  PRODUCT CHANGES - Licensee may amend, add to, subtract from or
               otherwise change from time to time its Finished Products,
               provided that all such changes and Finished Products comply with
               the terms and conditions of this Agreement;

          (B)  PRODUCT DOSAGE - Licensee shall formulate, manufacture and label
               all Finished Product in accordance with the required dosage
               described in Exhibits A ("Required Dosage");

          (C)  LABELING STATEMENTS - Licensee shall display the required
               labeling statements described in Exhibits A ("Required Labeling
               Statements"), on or in all labeling, advertising and promotional
               materials of its Finished Products in a manner that clearly
               associates the Required Labeling Statements with the Licensed
               Product;

          (D)  PATENTS - If and when they are issued, Licensee shall list the
               number(s) of all patents issued for Licensed Product ("Patents"),
               which are appropriate to the territory(ies) in which the Finished
               Product is sold, on or in all labeling, advertising and
               promotional materials of said Finished Products in a manner that
               clearly associates the Patents with the Licensed Product
               ("Required Patent Information"). As new Patents are issued, or
               the Required Patent Information changes, Company shall notify
               Licensee in writing and Licensee shall be provided a reasonable
               amount of time to update its labeling, advertising and
               promotional materials of its Finished Products to reflect the new
               Required Patent Information;

          (E)  LABEL REVIEW - Prior to distribution of its Finished Products,
               Licensee shall provide Company copies of its Finished Product
               labeling, advertising and promotional materials for pre-market
               approval by Company, which Company shall promptly review solely
               with respect to their compliance with this Agreement. Company
               shall promptly notify Licensee in writing of its acceptance or
               rejection of Licensee's Finished Product labeling, advertising
               and promotional materials with respect to their compliance with
               this Agreement. If rejected, Company shall inform Licensee of the
               changes necessary to be in compliance with this Agreement;



          (F)  PRODUCT QUALITY - Licensee shall (i) not blend nor formulate the
               Licensed Product with any other (-)hydroxycitric acid or Garcinia
               material, and (ii) not sell any Finished Products that are not
               manufactured in accordance with the requirements of the United
               States Federal Food, Drug and Cosmetic Act, including all
               applicable good manufacturing practice regulations, or, in the
               event Finished Products are manufactured or distributed in
               countries outside the United States, in accordance with all
               applicable laws and regulations of such countries;

          (G)  PRODUCT SUPPLY - Licensee agrees that it will not resell or
               supply any Licensed Product in bulk raw material form, either
               directly or indirectly, to any other third party, except for use
               in the manufacture of Licensee's Finished Products;

          (H)  SALES RECORDS - If requested by Company, Licensee shall provide
               Company a record of its Finished Product sales within fifteen
               (15) days of Company's written request. Company shall, at its
               sole option, have the right, at its own expense, to have an
               independent accounting firm acceptable to Licensee, whose
               acceptance shall not unreasonably be withheld, audit Licensee's
               Finished Product sales records during regular business hours, no
               more than once each calendar year and with at least five (5)
               business days prior written notice.

          (I)  THIRD PARTY COMPLIANCE - Licensee shall assure compliance with
               this Agreement by any third-party manufacturer or distributor of
               Finished Products, and guarantees performance of and payment
               under Company's General Purchase Agreement by any manufacturer
               which has purchased Licensed Product from Company for the
               manufacture of Finished Products under contract with Licensee;

          (J)  NEW MARKS - Licensee may use its own trademarks, tradenames,
               logos, advertising slogans and other related marks to identify
               Licensee and its Finished Products (collectively, "Other Marks")
               in Licensee's Materials, but agrees not to combine the Trademark
               with any Other Marks, words, letters or symbols, or otherwise
               alter the Trademark, to form one or more new marks ("New Marks"),
               without the express written consent of Company, which consent
               Company may withhold at its sole and absolute discretion.
               Licensee agrees that Company is the sole and exclusive owner of
               all right, title and interest in, and to, any New Marks, except
               those rights expressly granted to Licensee;

          (K)  TRADEMARK INFRINGEMENT - Licensee shall bring to the attention of
               Company any infringement or misuse of the Trademark which comes
               to Licensee's attention. Company shall indemnify, defend and hold
               Licensee harmless from any infringement or unfair competition
               proceedings involving the Trademark so long as Licensee is using
               the Trademark in compliance with this Agreement. Licensee shall
               not assert any claim based upon misuse or infringement of the
               Trademark without the prior written consent of Company;

          (L)  COMPLIANCE WITH LAWS - Licensee will comply with all laws and
               regulations relating or pertaining to the use of the Trademark
               and marketing of Finished Products;

          (M)  EXPENSES - Licensee will not create any expenses chargeable to
               Company; and

          (N)  INDEMNIFICATION - Except as provided in Section 5(k), Licensee
               indemnifies and holds Company harmless from any claims arising
               out of any act under or in violation of this Agreement by
               Licensee and its manufacturers and/or distributors, including,
               but not limited to, the distribution, advertising and promotion
               of Licensee's Finished Products, or use of the Information or
               Materials.

          (O)  FORMULATION EXCLUSION - Licensee shall not produce, market or
               sell any Finished Product(s) that contain a combination of
               (-)hydroxycitric acid (Garcinia), chromium and gymnemic acid
               (Gymnema) material, without the express written consent of
               Company.

     7.   TERM AND TERMINATION - This Agreement shall commence on the Effective
          Date and shall continue in full force and effect, unless and until
          terminated as follows:

          (a)  Company shall have the right to terminate this Agreement upon
               written notice to Licensee upon the breach of any provision of
               this Agreement,

          (b)  Licensee shall have the right to terminate this Agreement at any
               time upon written notice to Company, or



          (c)  Licensee's failure to purchase Licensed Product from Company
               during any consecutive twelve month period of time shall
               constitute on abandonment and automatic termination of this
               Agreement.

          Upon termination of this Agreement for any reason, Licensee shall
          immediately discontinue all use of the Trademark, Product Claims,
          Research, Materials and Information, except for publicly available,
          non-proprietary Information. Sections 6(k,m,n,o), 7 and 8 shall
          survive the termination of this Agreement.

     8.   GENERAL PROVISIONS:

          (A)  ASSIGNMENT - This Agreement is personal to Licensee. Licensee
               shall not assign or transfer any rights or obligations under this
               Agreement without the prior written consent of Company; provided,
               however, that Licensee may assign to any manufacturer with which
               Licensee contracts to produce any Finished Products any rights or
               obligations reasonably necessary to enable the manufacturer to
               produce the Finished Products. Any purported assignment without
               consent except as provided in this Section 8(a) will be null and
               void. This Agreement shall inure to the benefit of and be binding
               upon the parties and their successors and assigns;

          (B)  RELATIONSHIP - The relationship of the parties to this Agreement
               is determined solely by the provisions of this Agreement. The
               parties do not intend to create any agency, partnership, joint
               venture, trust or other relationship with duties or incidents
               different from those of parties to an arm's-length contract

          (C)  CHOICE OF LAW - This Agreement shall be construed in accordance
               with, and governed by, the internal laws of the State of
               California, without regard to conflicts of law;

          (D)  INTEGRATION - This Agreement sets forth the entire understanding
               of the parties relating to the transactions it contemplates, and
               supersedes all prior understandings relating to them, whether
               written or oral. There are no obligations, commitments,
               representations or warranties relating to them except those
               expressly set forth in these Agreements;

          (E)  ATTORNEY'S FEES - if any action is necessary to enforce the terms
               of this Agreement the prevailing party shall be entitled to
               reasonable attorneys' fees in addition to any other relief to
               which it may be entitled;

          (F)  SEVERABILITY - Should all or any portion of any provision of this
               Agreement be held unenforceable or invalid for any reason, the
               remaining portions or provisions shall be unaffected; and

          (G)  WEIVER/MODIFICATION/ AMENDMENT - No amendment of, supplement to
               or waiver of any obligations under this Agreement will be
               enforceable or admissible unless set forth in a writing signed by
               the party against which enforcement or admission is sought. No
               delay or failure to require performance of any provision of this
               Agreement shall constitute a waiver of that provision as to that
               or any other instance. Any waiver granted shall apply solely to
               the specific instance expressly stated.

IN WITNESS WHEREOF the parties have executed this Agreement as of the date
first written above.

LICENSEE

Company: Creative Enterprises Intl., Inc.
A Nevada Corporation
Address: 825 Lafayette Road
City, State, Zip: Bryn Mawn, Pa. 19010


Signature: /s/ Michael Salaman
           --------------------------
Name (Print): Michael Salaman
Title: President


COMPANY (INTERHEALTH)


SIGNATURE: /s/ Illegible
           --------------------------
Name (Print): _______________________
Title: EXEC. VP



                               EXHIBIT A - PRODUCT

PRODUCT NAME                        Super CitriMax(R) Clinical Strength

DESCRIPTION                         High solubility, non-hygroscopic, low
                                    sodium, potassium/calcium salt of
                                    (-)hydroxycitric acid extract, from the
                                    dried fruit rind of Garcinia cambogia
                                    (patent pending).

PRODUCT TYPES

   HCA-600-SXG                      Coarse powder for tableting and some
                                    encapsulating applications.

   HCA-6OO-SXM                      Medium mesh powder for multipurpose
                                    applications.

   HCA-600-SXS                      Soluble fine powder for food and beverage
                                    and some encapsulating applications.

SPECIFICATIONS*

   (-)Hydroxycitric Acid (mg/g)     600 +/- 50
   Calcium (mg/g)                   110 +/- 30
   Potassium (mg/g)                 160 +/- 40
   Sodium (mg/g)                    Less than 10

* For additional specifications, see Company's HCA-600-SXG, -SXM and -SXS
product specification sheets.

REQUIRED DOSAGE

   For dietary supplements          4500 mgs material providing 2700 mgs
                                    (-)hydroxycitric acid per day taken in three
                                    divided doses 30-60 minutes before meals.

   For functional foods and         1500 mgs material providing 900 mgs
   beverages                        (-)hydroxycitric acid per serving.
                                    Recommended three servings per day.

REQUIRED LABELING STATEMENTS

   (See Super CitriMax(R)           Super CitriMax(R) is a trademark of
   Clinical Strength Labeling       InterHealth N.I.
   Guidelines for correct usage     Super CitriMax brand of (-)hydroxycitric
   of Required Labeling             acid (patents-pending).
   Statements.)

REQUIRED PATENT INFORMATION*

     All countries         Patents-pending

     * To be listed in the Required Labeling Statement as indicated above or
     elsewhere in the labeling, advertising and promotional materials of
     Licensee's Finished Products in a manner that clearly associates the
     Patents and/or Patents Pending with the Licensed Product.

SUPER CITRIMAX CLINICAL STRENGTH LICENSING AGREEMENT
                                              FORM SCX-CS-TLA.DOC--March 3, 2004


                              EXHIBIT B - RESEARCH

PUBLICATIONS

     1.   Ohia SE, Awe O, LeDay AM, Opere CA, Bagchi D, Effect of Hydroxycitric
          Acid on Serotonin Release from Isolated Rat Brain Cortex, Research
          Communications in Molecular Pathology and Pharmacology,
          109:210-216, 2001.

     2.   Loe YC, Bergeron N, Rodriguez N, Schwarz J-M, Gas Chromatography/Mass
          Spectrometry Method to Quantify Blood Hydroxycitrate Concentration,
          Analytical Biochemistry, 292:148-154, 2001.

     3.   Westerterp-Plantenga MS, Kovacs EMR, The Effect of (-)-Hydroxycitrate
          on Energy Intake and Satiety in Overweight Humans. International
          Journal of Obesity, 26:870-872, 2002.

     4.   Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ, Safety and
          Mechanism of Appetite Suppression by a Novel Hydroxycitric Acid
          Extract (HCA-SX), Molecular and Cellular Biochemistry, 238: 89-103,
          2002.

     5.   Shara M, Ohia SE, Yasmin T, Zardetto-Smith A, Kincaid A, Bagchi M,
          Chatterjee A, Bagchi D, Stohs SJ, Dose- and Time-Dependent Effects of
          a Novel (-)-Hydroxycitric Acid Extract on Body Weight, Hepatic and
          Testicular Lipid Peroxidation, DNA Fragmentation and Histopathological
          Data over a Period of 90 D, Molecular and Cellular Biochemistry,
          254:339-346, 2003.

     6.   Preuss HG, Bagchi D, Bagchi M, Rao CVS, Satyanarayana S, Dey DK,
          Efficacy of a Novel, Natural Extract of (-)-Hydroxycitric Acid
          (HCA-SX) and a Combination of HCA-SX, Niacin-Bound Chromium and
          Gymnema sylvestre Extract in Eight Management in Human Volunteers,
          Nutrition Research 24:45-58, 2004.

     7.   Preuss HG, Bagchi D, Bagchi M, Rao CVS, Dey DK and Satyanarayana S,
          Efficacy of a Novel, Natural Extract of (-)-Hydroxycitric Acid
          (HCA-SX) and a Combination of HCA-SX, Niacin-Bound Chromium and
          Gymnema sylvestre Extract in Weight Loss, Diabetes, Obesity and
          Metabolism (In Press).

     8.   Shara M, Ohia SE, Schmidt RE, Yasmin T, Zardetto-Smith A, Kincaid A,
          Bagchi M, Chatterjee A, Bagchi D and Stohs SJ, Physico-chemical
          Properties of a Novel (-)-Hydroxycitric Acid Extract and Its Dose-and
          Time-dependent Effects on body Weight, Selected Organ Weights, Hepatic
          Lipid Peroxidation and DNA Fragmentation, Hematology and Clinical
          Chemistry, and Histopathological Changes Over a Period of 90 Days,
          Molecular and Cellular Biochemistry (In Press).

ABSTRACTS

     1.   Loe YC, Rodriguez N, Schwarz J-M, A New Mass Spectrometric Method to
          Quantify Blood Hydroxycitrate Concentration in Human Subjects, The
          FASEB Journal, 14:A212, Abs. 158.1, 2000.

     2.   Loe YC, Bergeron N, Phan J, Wen M, Lee J, Schwarz J-M, Time Course of
          Hydroxycitrate Clearance in Fasting and Fed Humans, The FASEB Journal,
          15:A632, Abs. 501.1, 2001.

     3.   Ohia SE, Awe SO, LeDay AM, Bagchi D, Effect of Hydroxycitric Acid on
          [(3)H]-5-HT Release from Rat Brain Cortex, The FASEB Journal, 15:A224,
          Abs. 207.13, 2001.

     4.   Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Mechanism of Appetite
          Suppresion by a Novel, Natural Hydroxycitric Acid, The Toxicologist,
          66 (1-S):188-189, Abs. 921, 2002.

     5.   Preuss HG, Bagchi D, Rao CVS, Echard BW, Satyanarayana S, Bagchi M,
          Effect of Hydroxycitric Acid on Weight Loss, Body Mass Index and
          Plasma Leptin Levels in Human Subjects, The FASEB Journal 16:A1020,
          Abs. 742.16, 2002.

     6.   Bagchi D, Preuss HG, Ohia SE, Rao CVS, Satyanarayana S, Bagchi M,
          Weight Management and Mechanism of Appetite Suppression by a Novel,
          Natural Extract of (-)-Hydroxycitric Acid, International Scientific
          Conference on Complimentary, Alternative & Integrative Medicine
          Research-Harvard University, Boston, MA, 9, Abs. 141, April
          12-14, 2002.

     7.   Bagchi D, Preuss HG, Rao CVS, Satyanarayana S, Bagchi M, Weight
          Management and Mechanisms of Action of a Novel, Natural Extract of
          (-)-Hydroxycitric Acid (HCA-SX) and a Combination of HCA-SX

SUPER CITRIMAX CLINICAL STRENGTH LICENSING AGREEMENT
                                              FORM SCX-CS-TLA.DOC--March 3, 2004


          Plus Niacin-Bound Chromium (NBC) and Gymnema sylvestre Extract (GSE),
          9th International Congress on Clinical Nutrition, London, UK, Abs.
          AB041, June 24-26, 2002.

     8.   Bagchi M, Preuss HG, Rao CVS, Bagchi D, Efficacy of a novel
          (-)-Hydroxycitric Acid Extract in Weight Management, Journal of the
          American College of Nutrition, 21:481, Abs. 61, 2002.

     9.   Bagchi D, Preuss HG, Rao CVS, Satyanarayana S, Bagchi M, Mechanisms of
          Weight Management by a Novel, Natural Extract of (-)-Hydroxycitric
          Acid (HCA-SX) and a Combination of HCA-SX Plus Niacin-Bound Chromium
          (NBC) and Gymnema sylvestre Extract (GSE), Journal of Tumor Marker
          Oncology, 17:55, Abs. A18, 2002.

     10.  Bagchi D, Preuss HG, Ohia SE, Rao CVS, Satyanarayana S and Bagchi M,
          Weight Management and Mechanism of Appetite Suppression by a Novel,
          Natural Extract of (-)-Hydroxycitric Acid, International Scientific
          Conference on Complementary, Alternative & Integrative Medicine
          Research, Boston, MA, April 12-14, 2002.

     11.  Debasis B, Weight Management & Mechanism of Appetite Suppression by a
          Natural Extract of (-)-Hydroxycitric Acid & a Combination of HCA-SX
          Plus Niacin-Bound Chromium (NBC) & Gymnema Sylvestre Extract (GSE),
          American Society of Bariatric Physicians Western Regional Obesity
          Course, Denver, CO, May 16-18, 2002.

     12.  Bagchi D, Preuss HG, Ohia SE, Rao CVS, Satyanarayana S and Bagchi M,
          Mechanism of Weight Management by a Novel, Natural Extract of
          (-)-Hydroxycitric Acid (HCA-SX) and a Combination of HCA-SX Plus
          Niacin-Bound Chromium (NBC) and Gymnema Sylvestre Extract (GSE), The
          2nd International Conference on Mechanisms and Actions of
          Nutraceuticals, Krems - Danube, Austria, October 6-9, 2002.

     13.  Ohia SE, Stohs SJ, Shara M, Yasmin T, Chatterjee A, Bagchi M,
          Zardetto-Smith A, Kincaid A and Bagchi D, 90-Day Chronic Toxicity
          Study of a Novel (-)-Hydroxycitric Acid Extract of Garcinia Cambogia,
          Society of Toxicology 42nd Annual Meeting & ToxExpo, Salt Lake City,
          Utah, March 9-13, 2003.

     14.  Bagchi D, Preuss HG, Ohia SE and Bagchi M, Molecular Mechanisms of
          Weight Management by a Novel, Natural Extract of (-)-Hydroxycitric
          Acid, 2003 American Association of Integrative Medicine (AAIM)
          National Conference San Antonio, TX, August 22-24, 2003.

SUPER CITRIMAX CLINICAL STRENGTH LICENSING AGREEMENT
                                              FORM SCX-CS-TLA.DOC--March 3, 2004


                           EXHIBIT C - TRADEMARK LOGO

Logo style for use in conjunction with Licensed Product (contact InterHealth for
electronic file):

[SuperCitrimax(R) LOGO]
Clinical Strength

SUPER CITRIMAX CLINICAL STRENGTH LICENSING AGREEMENT
                                              FORM SCX-CS-TLA.DOC--March 3, 2004


                       SUPER CITRIMAX(R) CLINICAL STRENGTH
                              MARKETING AGREEMENT

This agreement ("Agreement") is entered into this 9th day of June, 2004 by
InterHealth Nutraceuticals Incorporated, a California Corporation with its
principal place of business at 5451 Industrial Way, Benicia, CA 94510
("InterHealth") and Creative Enterprises Intl., Inc., a Nevada corporation with
its principal place of business at 825 Lafayette Road, Bryn Mawr, PA 19010
("Customer").

Whereas, InterHealth markets, distributes and sells a nutritional weight loss
ingredient under the tradename "Super CitriMax(R) Clinical Strength"
("Trademark"), which (a) is sold as a nutritional supplement, (b) is the subject
of certain patents pending ("Patents Pending"), and (c) meets the specifications
described in Exhibit A attached hereto, which may be updated in writing by
InterHealth from time to time (collectively referred to as "Product");

Whereas, Customer wishes to sell, market and distribute Product to be packaged
by Customer in end-user, finished packaged form as a nutritional supplement in
bottled water form only ("Finished Product") through Mass Market ("Channel")
located in the Untied States of America and it territories, Croatia, Australia,
Malaysia, Austria, Mexico, Belgium, New Zealand, Canada, Poland, Czech Republic,
Russia, Finland, South Africa, France, Sweden, Germany, Taiwan, Hong Kong,
Thailand, Japan, The Netherlands, Korea, United Kingdom ("Territory"); and

Whereas, InterHealth appoints Customer to sell Finished Product on a
non-exclusive basis in the Channel and in the Territory.

Customer agrees to:

     1.   Use commercially reasonable efforts to sell, distribute, advertise and
          promote Finished Product in the Channel and in the Territory solely
          under its Skinny Water brand.

     2.   Execute and comply with the terms of the Super CitriMax(R) Clinical
          Strength Licensing Agreement, including but not limited to, (a)
          Finished Product dosage and recommended use requirements, and (b)
          Finished Product labeling requirements, including (i) displaying the
          Trademark logo and identifying the Trademark as "a trademark of
          InterHealth N.I.," (ii) using the term "patent pending" in describing
          the Product, and (iii) listing all Patent numbers, as they are issued,
          on all packaging, advertising and promotional materials of Finished
          Product.

InterHealth agrees to:

     1.   Use commercially reasonable efforts to promptly fill Customer's orders
          for Product and to supply Product to Customer according to
          specifications.

     2.   Use commercially reasonable efforts to provide (a) technical support
          to Customer regarding Product, including information about the
          Product's safety and efficacy, physical and chemical properties, and
          applications and uses, and (b) ongoing marketing, research and
          intellectual property support for Product, to the extent InterHealth
          deems prudent.

     3.   Sell Product to Customer at the price of [****] F.O.B. Benicia,
          CA 94510. Said price shall apply to sales of Product to Customer,
          which are intended for use in the manufacture of Finished Product
          under the Skinny Water brand to be sold in the Channel and in the
          Territory only, and is subject to change upon 30 days written notice.



[*Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.]



______________________________________________________________________

___________                   ___________


/s/ Illegible        6/4/04   /s/ Illegible       6/22/04
------------------    Date    -----------------     Date
__________________            _________________